These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 6797060)

  • 1. Infections with Pseudomonas aeruginosa in the compromised host.
    Frøland SS
    Scand J Infect Dis Suppl; 1981; 29():72-80. PubMed ID: 6797060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interference of Pseudomonas aeruginosa with immunospecific host defenses.
    Petit JC; Daguet GL
    Biomed Pharmacother; 1983; 37(9-10):422-8. PubMed ID: 6232960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthetic peptide vaccine and antibody therapeutic development: prevention and treatment of Pseudomonas aeruginosa.
    Cachia PJ; Hodges RS
    Biopolymers; 2003; 71(2):141-68. PubMed ID: 12767116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of macrophage function for defence of the lung against Pseudomonas aeruginosa.
    Speert DP; Wong SY; Macdonald M; Sargeant R
    Behring Inst Mitt; 1997 Feb; (98):274-82. PubMed ID: 9382751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pseudomonas aeruginosa and Burkholderia cenocepacia infections in patients affected by cystic fibrosis: serum resistance and antibody response.
    Savoia D; Deplano C; Zucca M
    Immunol Invest; 2008; 37(1):19-27. PubMed ID: 18214797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune surveillance mechanisms of the skin against the stealth infection strategy of Pseudomonas aeruginosa-review.
    Andonova M; Urumova V
    Comp Immunol Microbiol Infect Dis; 2013 Sep; 36(5):433-48. PubMed ID: 23602428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pseudomonas aeruginosa infection and inflammation during contact lens wear: a review.
    Willcox MD
    Optom Vis Sci; 2007 Apr; 84(4):273-8. PubMed ID: 17435510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pseudomonas aeruginosa diversity in distinct paediatric patient groups.
    Tramper-Stranders GA; van der Ent CK; Wolfs TF; Kimpen JL; Fleer A; Johansen U; Johansen HK; Høiby N
    Clin Microbiol Infect; 2008 Oct; 14(10):935-41. PubMed ID: 18752596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccines and immunotherapy against Pseudomonas aeruginosa.
    Döring G; Pier GB
    Vaccine; 2008 Feb; 26(8):1011-24. PubMed ID: 18242792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The complement system and host defense against Pseudomonas endophthalmitis.
    Aizuss DH; Mondino BJ; Sumner HL; Dethlefs BA
    Invest Ophthalmol Vis Sci; 1985 Sep; 26(9):1262-6. PubMed ID: 4030253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of vaccine technology to prevention of Pseudomonas aeruginosa infections.
    Pier G
    Expert Rev Vaccines; 2005 Oct; 4(5):645-56. PubMed ID: 16221066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multi-valent human monoclonal antibody preparation against Pseudomonas aeruginosa derived from transgenic mice containing human immunoglobulin loci is protective against fatal pseudomonas sepsis caused by multiple serotypes.
    Lai Z; Kimmel R; Petersen S; Thomas S; Pier G; Bezabeh B; Luo R; Schreiber JR
    Vaccine; 2005 May; 23(25):3264-71. PubMed ID: 15837231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of innate and adaptive immunity in the pathogenesis of keratitis.
    Hazlett LD
    Ocul Immunol Inflamm; 2005; 13(2-3):133-8. PubMed ID: 16019672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL-10 is a major mediator of sepsis-induced impairment in lung antibacterial host defense.
    Steinhauser ML; Hogaboam CM; Kunkel SL; Lukacs NW; Strieter RM; Standiford TJ
    J Immunol; 1999 Jan; 162(1):392-9. PubMed ID: 9886412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccine strategies against Pseudomonas aeruginosa infection in the lung.
    Cripps AW; Dunkley ML; Clancy RL; Kyd J
    Behring Inst Mitt; 1997 Feb; (98):262-8. PubMed ID: 9382749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD1d-dependent macrophage-mediated clearance of Pseudomonas aeruginosa from lung.
    Nieuwenhuis EE; Matsumoto T; Exley M; Schleipman RA; Glickman J; Bailey DT; Corazza N; Colgan SP; Onderdonk AB; Blumberg RS
    Nat Med; 2002 Jun; 8(6):588-93. PubMed ID: 12042809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Corneal response to Pseudomonas aeruginosa infection.
    Hazlett LD
    Prog Retin Eye Res; 2004 Jan; 23(1):1-30. PubMed ID: 14766315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [When bacteria communicate with each other: the significance of intercellular signals in acute Pseudomonas aeruginosa infections].
    Van Delden C
    Rev Med Suisse Romande; 2000 Jan; 120(1):7-13. PubMed ID: 10705785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rationale for development of immunotherapies that target mucoid Pseudomonas aeruginosa infection in cystic fibrosis patients.
    Pier GB
    Behring Inst Mitt; 1997 Feb; (98):350-60. PubMed ID: 9382760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IgG subclasses and chronic bacterial infection. Subclass antibodies and the clinical course of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis.
    Pressler T
    APMIS Suppl; 1996; 66():1-41. PubMed ID: 8972694
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.